Sense antisense nonantisense. Can these novel antivirals knock HIV senseless?
Chang
H E
HE
Kraus Medical Partners, Clinical Research and Development, Los Angeles, CA.
Mascolini
M
M
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy; D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D001665:Binding Sites; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000188:drug therapy; D004279:DNA, Viral / Q000378:metabolism; D006678:HIV / Q000187:drug effects* / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D009690:Nucleic Acid Conformation; D020319:Oligodeoxyribonucleotides, Antisense; D016376:Oligonucleotides, Antisense / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D012367:RNA, Viral / Q000378:metabolism; D013873:Thionucleotides / Q000494:pharmacology / Q000627:therapeutic use
D000998:Antiviral Agents; D004279:DNA, Viral; D020319:Oligodeoxyribonucleotides, Antisense; D016376:Oligonucleotides, Antisense; D012367:RNA, Viral; D013873:Thionucleotides; C079996:GEM91